摘要
华蟾素注射液(Cinobutacini injection,CINO)是我国临床中应用较广的抗肿瘤中药制剂,尤其对原发性肝癌、肺癌、食管癌和胃癌具有较好的疗效。近年来,中药华蟾素注射液治疗肝癌、肺癌、胰腺癌的Ⅰ期临床研究已获得阶段成果,初步的实验结果显示,其抗肿瘤活性有效组分可能为其非极性部分。2005年该研究获得美国NCI U19课题立项资助,进行华蟾素注射液治疗胰腺癌的Ⅱ期临床研究。本文综述了华蟾素注射液及其活性成分在抑制肿瘤细胞增殖、诱导肿瘤细胞分化、促进肿瘤细胞凋亡、提高机体免疫力等方面的研究进展。
Abstract Huachansu Injection （Cinobutacini injection, CINO） is a traditional chinese drug with anti-cancer effects and widely used in clinical practice, especially for primary liver cancer, lung cancer, esophageal and stomach cancer. A phase Ⅰ study on Huachansu Injection in treating liver, lung and pancreatic cancer completed in 2005 and the results indicated that there were no dose-limit toxicity and severe side-effects and some patients got the good response for tumor regression. The further phase Ⅱstudy of Huachansu for the treatment of pancreatic cancer funded by U19 protocol supported by Amercian NCI. This paper reviewed the clinical studies of Huachansu injection for cancer treatment since 2000.
出处
《世界科学技术-中医药现代化》
2008年第4期126-130,共5页
Modernization of Traditional Chinese Medicine and Materia Medica-World Science and Technology
